CNS Delivery of Immunotherapy Using MSCs
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
A2006027
Acknowledgement
Summary
The focus of this proposal is on immunotherapy (vaccine) as an experimental approach to treat Alzheimer’s disease. Dr. Cribbs plans to directly delivery specific antibodies to the central nervous system to attack the toxic amyloid peptide that accumulates in the brain. The antibodies will be delivered by the patient’s own stem cells which will be isolated from their bone marrow. These stem cells will be genetically modified to make the antibodies, and then they will be injected into the brain where they will go to the sites of brain inflammation and secrete the therapeutic antibodies.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD